Updated November 2026 with the latest Phase 3 results.
I have been in the hair loss field for more than 30 years. I started Regrowth.com, the first hair-loss website, back when the only proven options were a topical solution and a surgeon's scalpel. Every year since, someone has promised me a "breakthrough." Most never reached a pharmacy shelf. So when people ask me about new hair loss treatments, I sort them into three buckets: what is approved, what is close, and what is still a lab story. Here is where things honestly stand right now.
Why New Hair Loss Treatments Take So Long
A new drug has to clear three phases of human trials, and hair is a slow outcome to measure. A follicle needs months to move through its growth cycle, so a trial for pattern hair loss usually runs at least six months, often a year, before anyone can say whether hair counts truly changed. That is why the list of FDA-approved options for androgenetic alopecia (pattern hair loss) has stayed short for decades: topical minoxidil and, for men, oral finasteride. Everything below should be read with that timeline in mind.
The Foundation: What Is Already Approved
Before chasing the newest headline, make sure the basics are covered. A 2024 review in American Family Physician still lists minoxidil and finasteride as first-line treatments for pattern hair loss.
- Topical minoxidil is over the counter for men and women. If you want a lighter, fast-drying format, our Regenepure Precision 5% Minoxidil Spray is the one I recommend.
- Finasteride is a prescription pill for men. Talk to a doctor or dermatologist about whether it fits you.
Most of the "new" treatments in development are not replacements for these. They are attempts to do the same jobs (block DHT at the scalp or wake up follicles) with fewer trade-offs.
New Hair Loss Treatments That Are Already FDA-Approved (For Alopecia Areata)
The biggest real-world change in the last few years came for alopecia areata, the autoimmune condition that causes patchy or total hair loss, not for pattern baldness. Three oral JAK inhibitors are now FDA-approved for severe alopecia areata:
- Baricitinib (Olumiant), approved in 2022 as the first systemic treatment for alopecia areata.
- Ritlecitinib (Litfulo), approved in 2023, including for patients 12 and older.
- Deuruxolitinib (Leqselvi), approved in 2024.
These are prescription drugs with boxed safety warnings, and they are not approved for ordinary male or female pattern hair loss. If you have patchy loss, a dermatologist visit is the right next step. The AAD's alopecia areata treatment page is a good primer.
The Most Promising Pipeline Treatments for Pattern Hair Loss
Extended-Release Oral Minoxidil (VDPHL01)
This one has moved fastest in 2026. Doctors already prescribe low-dose oral minoxidil off-label, but those tablets were made for blood pressure, not hair. Veradermics developed VDPHL01, an extended-release minoxidil pill designed to avoid the sharp blood-level peaks of regular tablets. In October 2026 its second Phase 3 trial (Study 304) in 536 men met both primary endpoints: at six months, non-vellus hair count rose by about 29 hairs/cm² with once-daily dosing and 36 hairs/cm² with twice-daily dosing, versus about 7 with placebo, according to Practical Dermatology. No treatment-related serious adverse events or cardiac events of special interest were reported through six months, though fluid retention and unwanted body hair did occur. A trial in women is expected to read out in the first half of 2027. If approved, it would be the first new hair-loss pill in the US since finasteride in 1997.
Clascoterone 5% Topical Solution
Clascoterone is a topical anti-androgen: it blocks DHT at the androgen receptor in the scalp, with the goal of avoiding the whole-body hormonal effects that worry some men about pills. The same molecule is already FDA-approved as a cream for acne. In late 2025, Cosmo Pharmaceuticals reported positive Phase III results (the SCALP 1 and SCALP 2 trials, 1,465 men across 51 centers) with target-area hair counts significantly better than placebo, as reported by Practical Dermatology. In April 2026, 12-month data showed men who stayed on clascoterone kept gaining hair, while those switched to placebo lost ground, with a safety profile similar to placebo. Cosmo plans to file with the FDA in early 2027. It is not yet approved for hair loss, and women were not the focus of those trials.
PP405 and "Wake-Up" Stem Cell Approaches
A different strategy targets the follicle stem cells that go dormant in thinning areas. PP405, a topical from Pelage Pharmaceuticals, aims to reactivate those cells rather than simply protect them from DHT. In a Phase 2a trial of 78 men and women, 31% of men with more advanced loss saw more than a 20% increase in hair density at eight weeks. The company has raised funding for Phase 3 trials, but the full data have not been published in a peer-reviewed journal yet. It is still years, not months, from a prescription pad.
Other Topical Anti-Androgens
Pyrilutamide (KX-826), another topical androgen-receptor blocker, met its primary endpoint in a pivotal Phase 3 trial in men in China in 2026, and its developer, Kintor, plans to seek approval there first. The same company's GT20029, which breaks down androgen receptors rather than just blocking them, had a positive Phase 2 trial. Neither is approved in the US. Topical finasteride is available through some compounding pharmacies, but that is a prescription conversation with your doctor.
Lab-Stage Ideas: Hair Cloning, Exosomes and Beyond
Hair cloning, follicle-growing in a dish and 3D bioprinting get a lot of press. I covered the real state of that science in Hair Cloning: Where the Science Really Stands. Short version: promising research, no approved product.
Exosome injections are being marketed by some clinics right now. The FDA has warned consumers that there are no FDA-approved exosome products. Be skeptical of anyone charging thousands of dollars for them.
How to Judge Any "New" Treatment You See Online
This is the part most articles skip, and after three decades it is the most useful thing I can give you. Ask five questions:
- Is it FDA-approved, and for what? "FDA-registered" or "FDA-cleared device" is not the same as an approved drug for hair loss.
- What phase is it in? Phase I and II results are small and often do not hold up in Phase III.
- Was it compared to placebo? Hair loss trials have a strong placebo effect. Without a control group, a "70% improvement" claim means very little.
- How long was the study? Anything under six months for pattern hair loss is too short to trust.
- Who is selling it? If the only people talking about it are the people selling it, wait.
What I Would Do Today
Do not wait for the next drug. The follicles you keep now are the ones a future treatment can work on. Get a proper diagnosis, because the right treatment depends on whether you have pattern loss, shedding such as telogen effluvium, or an autoimmune condition. Start with the proven foundation, take photos every three months, and add new options only when they have real Phase III data behind them. My broader game plan is in How to Regrow Hair.
FAQ
What is the newest FDA-approved hair loss treatment?
For alopecia areata, deuruxolitinib (2024) is the most recent. For pattern hair loss, no new drug has been approved in decades; minoxidil and finasteride remain the approved options.
Which new pattern hair loss treatment is closest to approval?
Extended-release oral minoxidil (VDPHL01) and clascoterone 5% solution both have positive Phase 3 data in men. Clascoterone's FDA filing is planned for early 2027. Neither is approved yet.
Is clascoterone available for hair loss?
Not yet as an approved hair loss product. Phase III results in men were positive, including 12-month data, and an FDA filing is planned for early 2027.
Will new treatments replace minoxidil?
Probably not soon. Most pipeline drugs target DHT, which minoxidil does not, so they are more likely to be added alongside it than to replace it. The one exception is a better-designed oral minoxidil, which would be a new way to take the same drug.
Are JAK inhibitors used for male pattern baldness?
No. They are approved only for severe alopecia areata and carry significant safety warnings. Talk to a dermatologist about any prescription treatment.
This article is for education only and is not medical advice. Hair loss has many causes; see a doctor or board-certified dermatologist for a diagnosis and treatment plan.